Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Published 2019 View Full Article

Authors

Keywords

Journal

LANCET

Volume 394, Issue 10212, Pages 1929-1939

Publisher

Elsevier BV

Online

2019-10-05

DOI

10.1016/s0140-6736(19)32222-6

Ask authors/readers for more resources

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

LANCET

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Publish scientific posters with Peeref

Create your own webinar